Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KDR act mut |
| Therapy | Sorafenib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KDR act mut | Advanced Solid Tumor | sensitive | Sorafenib | Preclinical | Actionable | In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655). | 19723655 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (19723655) | KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. | Full reference... |